FGF21 analogs or FGF21 receptor agonists might represent an alternative treatment for NAFLD, obesity–associated type 2 diabetes, and other aging–associated metabolic diseases. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.